1. Home
  2. TVRD vs NODK Comparison

TVRD vs NODK Comparison

Compare TVRD & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • NODK
  • Stock Information
  • Founded
  • TVRD 2017
  • NODK 1946
  • Country
  • TVRD United States
  • NODK United States
  • Employees
  • TVRD N/A
  • NODK N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • NODK Property-Casualty Insurers
  • Sector
  • TVRD Health Care
  • NODK Finance
  • Exchange
  • TVRD Nasdaq
  • NODK Nasdaq
  • Market Cap
  • TVRD 246.5M
  • NODK 277.0M
  • IPO Year
  • TVRD N/A
  • NODK 2017
  • Fundamental
  • Price
  • TVRD $33.88
  • NODK $13.35
  • Analyst Decision
  • TVRD Strong Buy
  • NODK
  • Analyst Count
  • TVRD 5
  • NODK 0
  • Target Price
  • TVRD $59.20
  • NODK N/A
  • AVG Volume (30 Days)
  • TVRD 22.1K
  • NODK 11.6K
  • Earning Date
  • TVRD 08-14-2025
  • NODK 11-06-2025
  • Dividend Yield
  • TVRD N/A
  • NODK N/A
  • EPS Growth
  • TVRD N/A
  • NODK N/A
  • EPS
  • TVRD N/A
  • NODK 0.07
  • Revenue
  • TVRD N/A
  • NODK $310,389,000.00
  • Revenue This Year
  • TVRD N/A
  • NODK N/A
  • Revenue Next Year
  • TVRD N/A
  • NODK N/A
  • P/E Ratio
  • TVRD N/A
  • NODK $189.43
  • Revenue Growth
  • TVRD N/A
  • NODK N/A
  • 52 Week Low
  • TVRD $8.13
  • NODK $12.01
  • 52 Week High
  • TVRD $36.71
  • NODK $17.24
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 66.16
  • NODK 55.16
  • Support Level
  • TVRD $29.33
  • NODK $12.85
  • Resistance Level
  • TVRD $31.88
  • NODK $13.60
  • Average True Range (ATR)
  • TVRD 2.09
  • NODK 0.27
  • MACD
  • TVRD 0.49
  • NODK 0.05
  • Stochastic Oscillator
  • TVRD 69.21
  • NODK 76.56

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About NODK NI Holdings Inc.

NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.

Share on Social Networks: